Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis - Scorecard - MDSpire
Advertisement
Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis
Clinical Scorecard: Exploring Genomic Variations in Cerebrospinal Fluid: A Comparison of Lung Cancer Patients with Combined Brain and Meningeal Metastases versus Isolated Meningeal Metastases
At a Glance
Category
Detail
Condition
Lung adenocarcinoma with brain metastases including brain parenchymal metastasis (BM) and meningeal metastasis (MM)
Key Mechanisms
EGFR mutations driving tumor proliferation and survival; genomic variations in CSF reflecting intracranial metastatic profiles; differences in tumor microenvironment between BM and MM
Target Population
Patients with lung adenocarcinoma and confirmed brain metastases (BM and/or MM)
Care Setting
Specialized oncology and neurology centers with access to imaging and CSF genomic testing
Key Highlights
Lung adenocarcinoma patients with brain metastases have poor prognosis, especially those with meningeal metastases (median survival 3-6 months).
CSF liquid biopsy better reflects genetic alterations in intracranial lesions compared to plasma due to blood–brain barrier limitations.
EGFR mutations (exons 18–21) are common drivers in LUAD and influence metastatic behavior and treatment response.
Guideline-Based Recommendations
Diagnosis
Confirm brain metastases via enhanced MRI distinguishing BM, MM, or both.
Use CSF liquid biopsy to detect genomic alterations for intracranial lesions due to low plasma ctDNA sensitivity.
Management
Consider EGFR-TKI therapy for patients with EGFR-mutated LUAD brain metastases.
Develop treatment strategies tailored to metastatic patterns (BM vs MM) informed by CSF genomic profiling.
Monitoring & Follow-up
Monitor CSF genomic profiles to guide targeted therapy adjustments and detect resistance mechanisms.
Risks
Recognize poor prognosis associated with meningeal metastases and combined BM and MM.
Be aware of drug resistance challenges in EGFR-TKI treatment.
Patient & Prescribing Data
Patients with lung adenocarcinoma and brain metastases undergoing CSF genomic testing
EGFR mutations detected in CSF can guide targeted EGFR-TKI therapy; however, resistance remains a challenge requiring further research.
Clinical Best Practices
Utilize CSF liquid biopsy for accurate genomic profiling of intracranial metastases.
Differentiate metastatic patterns (BM vs MM) to inform prognosis and treatment planning.
Incorporate molecular profiling into clinical decision-making to personalize therapy.
Ensure patient eligibility criteria include confirmed LUAD diagnosis, brain metastasis imaging, and adequate performance status.
